

1 **The potential health impact and healthcare cost savings of** 2 **different sodium reduction strategies in Canada**

3
4 Nadia Flexner^{1*}, Amanda C. Jones², Ben Amies-Cull³, Linda Cobiac⁴, Eduardo Nilson^{5,6}, Mary
5 R. L'Abbe^{1*}

6
¹Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.

²Department of Public Health, University of Otago, Wellington, New Zealand.

³Nuffield Department of Primary Care Healthcare Sciences, University of Oxford, Oxford, United Kingdom.

⁴Griffith University, Queensland, Australia.

⁵Center for Epidemiological Research in Nutrition and Public Health, University of São Paulo, São Paulo, Brazil.

⁶Oswaldo Cruz Foundation (Fiocruz/Brasilia), Brasilia, Brazil.

*Corresponding authors: mary.labbe@utoronto.ca; nadia.flexner@mail.utoronto.ca

7 **Keywords:** sodium reduction, health impact, cardiovascular disease, cost-utility analysis, multi-
8 state lifetable model, food policy.

9 10 **Abstract**

11 **Background**

12 High dietary sodium is the main dietary risk factor for non-communicable diseases due to its
13 impact on cardiovascular diseases, the leading cause of death globally. The Government of
14 Canada has taken measures to reduce average dietary sodium intakes, such as setting voluntary
15 sodium reduction targets for packaged foods and recently approving regulations mandating 'high
16 in' front-of-pack labeling (FOPL) symbols.

17 **Objectives**

18 To estimate the number of avoidable ischemic heart disease (IHD) and stroke incidence cases,
19 and their associated healthcare cost and Quality-Adjusted Life Year (QALY) savings resulting
20 from different sodium reduction strategies and recommendations in Canada.

21 **Methods**

22 We used the PRIMETIME model, a proportional multi-state lifetable model. Outcomes were
23 modeled over the lifetime of the population alive in 2019, at a 1.5% discount rate, and from the
24 public healthcare system perspective. Nationally representative data were used as inputs for the
25 model.

26 **Results**

27 Fully meeting Health Canada's sodium reduction targets was estimated to prevent 219,490 (95%
28 UI, 73,409–408,630) cases of IHD, and 164,435 (95% UI, 56,121–305,770) strokes. This led to a
29 gain of 276,185 (95% UI, 85,414–552,616) QALYs, and healthcare costs savings of CAD\$
30 4,212(95% UI, 1,303–8,206) million over the lifetime of the 2019 cohort. Sodium reduction
31 intake through FOPL regulations has the potential to prevent between 35,930 (95% UI, 8,058–
32 80,528) and 124,744 (95% UI, 40,125–235,643) cases of IHD, and between 26,869 (95% UI,
33 5,235–61,621) and 93,129 (95% UI, 30,296–176,014) strokes. This results in QALY gains
34 ranging from 45,492 (95% UI, 10,281–106,579) to 157,628 (95% UI, 46,701–320,622), and
35 healthcare costs savings ranging from CAD\$ 695 (95% UI, 160–1,580) to CAD\$ 2,415 (95% UI,
36 722–4,746) million over the lifetime of the 2019 Canadian cohort. Greater health and healthcare
37 costs gains were estimated if Canadians were to meet the population-level sodium intake

38 recommendations of the World Health Organization (2,000 mg/day) and the Adequate Intake
39 recommendation (1,500 mg/day). All sodium reduction strategies tested were cost saving.

40 **Conclusions**

41 Reducing population-level sodium intakes is feasible and has the potential to improve health
42 outcomes and save healthcare costs in Canada. From interventions tested, most health and
43 healthcare costs gains were attributed to fully meeting sodium reduction targets, which highlights
44 the importance of changing the voluntary nature of these targets to mandatory. A combination of
45 strategies, mandatory sodium reduction targets and implementation of the ‘high in’ FOPL
46 symbol would provide the most benefit from a public health standpoint.

47 **1. Introduction**

48 Diets high in sodium are the main dietary risk factor for non-communicable diseases (NCDs)(1)
49 due to their impact on cardiovascular diseases (CVDs)(2, 3), the leading cause of death globally
50 and a major contributor to disability, particularly in relation to diseases such as ischemic heart
51 disease (IHD) and stroke(4). In Canada, CVDs (mostly IHD and strokes) rank as the second
52 leading cause of death (after cancers), accounting for 25% of all deaths each year(5). The World
53 Health Organization (WHO) broadly considers reducing population-level dietary sodium intake
54 to be a cost-effective measure that could save many lives by decreasing and preventing the
55 burden of diet-related NCDs, mainly from CVDs, and save costs in the long run(6, 7).

56 The WHO recommends consuming less than 2,000 mg/day of sodium (5 g/day of salt)(8);
57 however, intake levels around the world largely exceed recommendations(8). Canada is not an
58 exception, as recent sodium intake estimations showed that Canadians consume an average of
59 2,760 mg/day of sodium(9, 10), with 63.9% of Canadian adults exceeding the recommendation
60 for Chronic Disease Risk Reduction (CDRR) levels (2,300 mg/day) and only 9.4% of Canadian
61 adults meeting the Adequate Intake (AI) levels (1,500 mg/day)¹⁰.

62 Reducing sodium intake is a WHO ‘best buy’ recommendation for the prevention and control of
63 NCDs(6). In its *SHAKE Technical Package for Salt Reduction*(11), WHO recommends ideally
64 implementing a joint combination of measures to reduce population-level sodium intakes. These
65 measures include monitoring salt use (e.g., intakes, salt content in foods), promote food
66 reformulation to contain less salt by setting salt targets levels in foods, adopting interpretive
67 front-of-pack labeling systems, and restricting marketing of foods ‘high in’ salt, among
68 others(11).

69 The Canadian government has implemented and adopted several evidence-based policies to
70 make the healthier choice easier for all Canadians, as described in the *Canadian Healthy Eating*
71 *Strategy* (2016)(12). As part of this comprehensive strategy, Health Canada committed to
72 ongoing collaboration with stakeholders in the food industry to reduce sodium levels in packaged
73 foods through updating the voluntary sodium reduction targets for processed foods (2020-
74 2025)(13). It is worth noting that progress evaluations of the previous (2012-2016) set of
75 voluntary sodium reduction targets have only shown modest results(14), and only minor
76 revisions have been made to the latest set of targets (2020-2025)(13). In addition, Health Canada
77 recently approved front-of-pack labeling (FOPL) regulations that will require packaged foods
78 that meet or exceed established thresholds for nutrients-of-concern, including sodium, to display
79 a ‘high in’ FOPL nutrition symbol, to come into effect by January 2026(15).

80 Estimating the impact of public health polices, such as the aforementioned, could be challenging
81 or simply not feasible using traditional epidemiological research methods such as cohort studies,
82 randomized control trials or natural experiments. Policy scenario modeling has proven to be an
83 appropriate and strategic tool for estimating the health and economic impact of public health
84 policies prior to actual implementation(16). Specifically, NCD policy scenario modeling allows
85 us to predict the cumulative health outcomes of interventions over the long term and across the
86 entire population; in addition to providing evidence on what the magnitude would be to take
87 action or not by comparing different policy scenarios with a ‘business as usual’ scenario(17).

88 A systematic review of previous policy scenario modeling studies have demonstrated the cost-
89 effectiveness of reducing dietary sodium intake(18). Studies in the Canadian context have
90 estimated the economic and health impact of reducing sodium intake to recommended levels
91 when compared to previous sodium intake levels (i.e., 3,800 mg/day) using data from CCHS-

92 Nutrition 2004(19). More recently, using data from CCHS-Nutrition 2015, we previously
93 estimated the number of CVDs deaths that could be averted or delayed if Canadians were to
94 reduce their sodium intake to recommended levels(10, 19), and as a result of implementing ‘high
95 in’ FOPL regulations(20, 21). However, to the best of our knowledge, no study in Canada has
96 previously estimated the health impact and healthcare cost savings from ‘real world’ policy
97 scenario options to reduce population level dietary sodium intakes (i.e., food reformulation and
98 mandatory ‘high in’ FOPL symbol).

99 In this study, we aimed to provide policymakers and stakeholders with evidence supporting
100 policy options to reduce excess dietary sodium intakes in Canada. We estimated the number of
101 avoidable ischemic heart disease and stroke incidence cases, and their associated healthcare cost,
102 and Quality-Adjusted Life Year (QALY) savings resulting from 1) meeting sodium intake
103 recommended levels, 2) meeting sodium reduction targets for packaged foods established by
104 Health Canada, and 3) implementing ‘high in’ front-of-pack labeling regulations in Canada.

105 **2. Materials and methods**

106 We conducted a cost-utility analysis using a public healthcare system perspective. The potential
107 health and healthcare costs impact of reducing dietary sodium intake were modelled by
108 comparing ten counterfactual scenarios (described below in section ‘*Counterfactual scenarios*
109 *modeled*’) to a ‘business as usual’ or ‘baseline’ scenario. Outcomes were modeled over the
110 lifetime of the Canadian population alive in 2019, and a 1.5% discount rate was applied to both
111 health gains and healthcare costs, as recommended by the Canadian Agency for Drugs and
112 Technologies in Health (CADTH)(22).

113 *2.1 PRIMETIME model: a proportional multi-state lifetable model*

114 The PRIMETIME model, an established and robust proportional multi-state lifetable model, was
115 used in this study(23, 24). PRIMETIME is an epidemiological model tool, developed by
116 researchers at the University of Oxford, that has been widely applied to a range of different diet
117 and obesity policy scenarios in the UK and other countries(24-31). This model has been designed
118 for policy scenario evaluation and can be utilized to assess future effects of policies in order to
119 help policymakers set priorities for action. In a world of limited resources, governments are
120 increasingly required to properly assess the cost-effectiveness of interventions to strategically
121 allocate their resources. The PRIMETIME model is a tool for policy support and prioritization that
122 under the same set of assumptions can help compare different policy options by assessing the
123 cost-effectiveness of interventions.

124 The PRIMETIME model is comprised of the following interconnected modules: a risk factor
125 exposure module, a series of disease models, and a lifetable. Detailed methods of the model have
126 been published elsewhere(24). Briefly, PRIMETIME uses epidemiological data collected mainly
127 from meta-analyses of randomized control trials or prospective cohort studies to parameterize the
128 relationships between risk factors and NCDs. This can be modeled as direct effects of risk factors
129 or via their intermediate risk factors (i.e., blood pressure, BMI, or total cholesterol), where
130 appropriate. The Canadian PRIMETIME Salt model includes the two main CVDs associated with
131 high consumption of salt/sodium, IHD and stroke. These diseases are modeled in PRIMETIME in
132 a three-state Markov model in which the population is either in a disease-free state, a diseased
133 state, or dead. Then, the lifetable combines these simulated changes in population health and
134 healthcare system as a result of changes in disease epidemiology.

135 We adapted the PRIMETIME model to the Canadian context by collecting, processing, and
136 analyzing Canadian-specific and nationally representative data (i.e., dietary sodium intakes,
137 population demographics, disease epidemiology and healthcare costs). **Table 1** shows the data
138 sources used as inputs for the PRIMETIME model in Canada. A closed cohort analyses was
139 performed, taking the Canadian adult population as a baseline (≥ 19 y) over the lifetime of the
140 cohort or until they reach 100y of age.

141 *2.2 Model input parameters*

142 *Population inputs*

143 Canadian population size and all-cause mortality data by 1-year age/sex groups were included in
144 the model. Data was obtained from the publicly available Statistics Canada CANSIM tables for
145 the year 2019 (**Table 1, Supplementary Table S1**). All-cause mortality data was only available
146 in 5-year age/sex groups; thus, further processing was required. Data was interpolated to 1-year
147 using a temporal disaggregation method(32).

148 *Disease epidemiology*

149 Data on incidence, prevalence and disease-specific mortality were collected for ischemic heart
150 disease and stroke for the year 2019 (**Table 1**). First, we prioritized alignment of WHO
151 International Statistical Classification of Diseases and Related Health Problems 10th Revision
152 (ICD-10) codes(33) between disease epidemiology and healthcare cost data (described below).
153 Disease epidemiology data was only available in 5y age/sex groups up to age 90+ for all
154 parameters; thus, further processing was required. Data was extrapolated to age 100+ using a
155 polynomial trend line (**Supplementary Table S2**). Then, health data estimates were interpolated

156 to 1y age/sex groups using a temporal disaggregation method to obtain smooth disaggregated
157 counts, while maintaining the aggregated total(32).

158 Case fatality rates were derived from cause-specific incidence, prevalence and mortality data,
159 together with population size using a Bayesian approach, the *disbayes* optimization method built
160 on the Stan software (*disbayes* package available in R)(32, 34). It was assumed that case fatality
161 was constant for all ages below 35. The *disbayes* package estimates case fatality using a three-
162 state transition process of disease free, disease, or death. The *disbayes* ' approach and
163 assumptions are consistent with the ones underpinning disease simulation in the PRIMEtime
164 model (**Supplementary Table S1**).

165 Mean systolic blood pressure (SBP) estimates for the year 2019 were acquired. Data was
166 available by sex (male, female) and age group (6-11 years, 12-19, 20-39, 40-59, 60-79) (**Table**
167 **1**). As SBP measurements were not available for individuals aged 80 years and older, we
168 assumed the same values as those observed for 60-79 years age/sex groups for individuals in the
169 80+ years group.

170 *Dietary sodium intake*

171 This study used data from the Canadian Community Health Survey (CCHS)-Nutrition 2015 to
172 estimate baseline and counterfactual dietary sodium intakes for Canadian adults (≥ 19 y). CCHS-
173 Nutrition 2015 is a nationally representative, cross-sectional health and nutrition survey that
174 utilized 24-hour (24h) dietary recalls to collect data on food and beverage intake across the 10
175 Provinces of Canada (aged 1y or older)(35). We used both available days of 24h dietary recalls
176 to estimate usual dietary sodium intakes for adults by Dietary Reference Intakes (DRI)(36)

177 age/sex groups (i.e., males and females ages 19-30, 31-50, 51-70, 71+), methods that have been
178 previously published by our research group(10, 20, 21).

179 *Counterfactual scenarios modeled*

180 *Meeting sodium intake recommended levels (Scenarios 1 and 2)*

181 We modeled potential health and healthcare costs gains from meeting WHO sodium intake
182 recommendations of 2,000 mg/day and the AI recommendations of 1,500 mg/day. The
183 proportion needed to meet these recommendations from the current sodium intakes (2,758
184 mg/day) was calculated and applied to each DRI age/sex group to build our counterfactual
185 scenarios¹⁰ (**Table 2, Supplementary Table S3**).

186 *Meeting sodium reduction targets established by Health Canada (Scenario 3)*

187 Fully meeting Health Canada’s voluntary sodium reduction targets for packaged foods was used
188 as one of the counterfactual scenarios tested in this study. Our research group has previously
189 published methods for this policy modeling approach(10, 37). Briefly, data from a Canadian
190 branded packaged food composition database, the University of Toronto’s Food Label
191 Information and Price database (FLIP 2017), was linked to the Food and Ingredient Details (FID)
192 file in the CCHS-Nutrition 24-hour recall to estimate baseline and counterfactual dietary sodium
193 intakes. The counterfactual scenario was estimated after conducting a systematic ‘reformulation’
194 of eligible packaged foods to meet Health Canada’s sodium reduction targets¹⁰ (**Table 2,**
195 **Supplementary Table S3**).

196 *Implementing ‘high in’ front-of-pack labeling regulations (Scenarios 4-10)*

197 Based on recent FOPL evidence from observational and experimental studies(38-40), we
198 estimated potential changes to dietary sodium intakes(20). These studies estimated changes in
199 the content of nutrients of public health concern (i.e., saturated fats, sodium, and sugars) in food
200 and beverage purchases when a ‘high in’ FOPL was in place. We assumed that changes observed
201 in food and beverage purchases would carry over to dietary intakes, as evidence suggests that
202 documented food purchases can serve as a reasonably precise estimate of overall diet quality(41).
203 We modeled changes in overall food and beverage sodium content based on early evaluations of
204 the Chilean Food Labeling and Marketing Law (-4.7%)(38) (*Scenario 4*), the criteria used by
205 WHO to estimate FOPL cost-effectiveness as part of the *Technical briefing for Appendix 3 of the*
206 *Global Action Plan for NCDs* (-6.4%)(40) (*Scenario 5*), and a FOPL systematic review and
207 network meta-analysis (-7.8%)(39) (*Scenario 6*), (**Table 2, Supplementary Table S3**).

208 Furthermore, we constructed counterfactual scenarios using data from consumer research
209 reporting the proportion of consumers that choose or were willing to choose products with fewer
210 ‘high in’ FOPL symbols(42-47). We first identified foods and beverages in FLIP 2017 similar to
211 those reported in CCHS-Nutrition 2015 that would display at least one fewer ‘high in’ FOPL
212 symbol for nutrients of concern, including sodium. Then, to estimate ‘new’ dietary intakes, we
213 replaced nutritional values of identified foods for a random sample of 30%, 50%, and 70% of
214 *CCHS-Nutrition* adult participants that consume at least one food that would display a ‘high in’
215 symbol (*Scenarios 7-9*). Additionally, to estimate the potential maximum effect of FOPL, we
216 simulated changes for all adult participants (*Scenario 10*) (**Table 2, Supplementary Table S3**).

217 All FOPL counterfactual scenarios tested in this study are based on ‘high in’ FOPL evidence,
218 which is the FOPL system recently approved in Canada. We have previously published methods

219 for all FOPL policy scenarios(20, 21). For this study, we used potential impacts of implementing
220 FOPL only for changes in sodium intakes.

221 *Direct healthcare costs*

222 This study followed the perspective of the public healthcare system. The model estimated direct
223 healthcare cost differences between the baseline and the modeled intervention. We used data
224 from the 2010 Economic Burden of Illness in Canada (EBIC)(48), the most recent available and
225 comprehensive national disease-specific costs study. Direct healthcare costs in EBIC 2010 are
226 reported by diagnostic category disaggregated by age/sex groups.

227 We followed previous published methods for the estimation of direct healthcare costs for each of
228 the modeled diseases(49) (i.e., total and by prevalence case). We prioritized alignment of WHO
229 ICD-10(33) codes between prevalence case data with EBIC 2010 categories, as well as disease
230 definition as closely as possible with the Global Burden of Disease study (2019)(50). Therefore,
231 we first identified the best fitting EBIC diagnostic category by matching ICD-10 codes for each
232 disease under study. We used the EBIC 2010 online tool to produce costs for each EBIC
233 category by sex (male, female) and age group (0-14 years, 15-34, 35-54, 55-64, 65-74, 75+)(51).
234 Direct healthcare costs are comprised of attributable (drug, hospital care – day surgery, hospital
235 care – inpatient, hospital care – other ambulatory care, hospital care – outpatient – clinic, hospital
236 care – outpatient – emergency, and physician care) and unattributable direct costs (other
237 institutions, other professionals, capital, public health, administration, and other health
238 spending).

239 EBIC diagnostic categories only provide disease-specific estimates for attributable direct costs,
240 but also report total unattributable direct costs; thus, unattributable direct costs were estimated

241 and added to cost estimates per disease. The proportion of each modeled disease's share to the
242 total attributable direct cost was estimated for each age/sex group using a method developed by
243 Krueger et al(52). Subsequently, this proportion was applied to the total unattributable direct
244 costs to then include these estimates in the total direct healthcare costs for each disease. Costs
245 per disease case were then calculated by dividing estimated direct healthcare costs for each
246 age/sex group by prevalent cases in 2010, yielding the cost per case per year. A decision was
247 made on using prevalent cases for each disease based on their clinical pattern of exerting costs;
248 hence, these were treated as prevalent cases. Lastly, healthcare costs were inflated to 2019
249 Canadian Dollars (CAD), and inflation factor was estimated using the 'health care' sub-index
250 from the Statistics Canada Consumer Price Index(53). Methods, sources, and direct healthcare
251 costs estimations, by each modeled disease, are described in **Table 1** and **Supplementary**
252 **Tables S4 and S5**.

253 *2.3 Sensitivity analysis*

254 Sensitivity analysis was conducted to examine the impact of uncertainty in the discount rate by
255 applying 0% and 3% discount rate, as recommended by the CADTH(22). Additionally, we also
256 used time horizons of 10 and 50 years.

257 *2.4 Statistical analysis*

258 The National Cancer Institute (NCI) method(54) was used to estimate Canadian adults' usual
259 sodium intakes and distributions for all adults and by DRI age/sex group (baseline and
260 counterfactual scenarios). The 1-part (amount only) model was used as zero consumption of
261 sodium was <5%, as recommended by Davis et al(55), which also allowed us to stratify analysis

262 by DRI age/sex groups and to remove outliers for implausible sodium intakes. Confidence
263 intervals and standard error were estimated using the bootstrap balanced repeated replication
264 method (500 replicates). Additionally, we applied sample survey weights (Statistics Canada) to
265 all analyses to ensure nationally representative estimates(35). Statistical analyses were conducted
266 using SAS version 9.4.

267 After inputting all the required data in PRIMETIME, the model estimated the avoidable ischemic
268 heart disease and stroke incidence cases, healthcare costs savings, and QALYs for each
269 counterfactual scenario, by sex and each disease of interest. Uncertainty intervals (95% UI) were
270 produced using Monte Carlo simulation at 5000 iterations to allow the epidemiological
271 parameters in PRIMETIME to fluctuate randomly following the distributions considered in the
272 model(24).

273 **3. Results**

274 *Meeting sodium intake recommendations*

275 Fully meeting Health Canada's sodium reduction targets was estimated to reduce mean sodium
276 intakes to the national sodium intake recommendations (~2,300 mg/day; 17% reduction from
277 current levels). This reduction in sodium intake was estimated to prevent 219,490 (95% UI,
278 73,409 – 408,630) incident cases of IHD, and 164,435 (95% UI, 56,121 – 305,770) strokes.
279 Approximately, 63% of prevented IHD cases were estimated in males (137,188 [95% UI, 44,185
280 – 259,658]) and 37% in females (82,303 [95% UI, 29,224 – 148,972]), and 57% of prevented
281 strokes were estimated in males (94,522 [95% UI, 31,032 – 179,060]) and 43% in females
282 (69,913 [95% UI, 25,088 – 126,710]). These health gains result in an overall gain of 276,185

283 QALYs (95% UI, 85,414 – 552,616), with 62% attributed to males and 38% to females. This
284 translates into CAD\$ 4,212 million (95% UI, CAD\$ 1,303 – CAD\$ 8,206) in healthcare cost
285 savings (69% in males, 31% in females) over the lifetime of the 2019 Canadian cohort (**Tables 3**
286 **and 4, Figure 1 and 2**).

287 Greater health and healthcare cost gains were estimated if Canadians were to meet WHO's
288 population-level sodium intake recommendations (2,000 mg/day) and the Adequate Intake
289 recommendation (1,500 mg/day) (**Tables 3 and 4, Figure 1 and 2**).

290 *Implementing 'high in' front-of-pack labeling regulations*

291 Sodium intake reduction through the implementation of FOPL regulations, as suggested by early
292 evaluations of the Chilean FOPL regulations, has the potential to prevent 57,023 (95% UI,
293 17,350 – 114,447) incident cases of IHD, and 41,794 (95% UI, 12,389 – 85,302) strokes.
294 Approximately 64% of prevented IHD cases were estimated in males (36,323 [95% UI, 10,526 –
295 73,593]) and 36% in females (20,701 [95% UI, 6,824 – 40,854]), and 58% of prevented strokes
296 were estimated in males (24,443 [95% UI, 7,028 – 50,943]) and 42% in females (17,351 [95%
297 UI, 5,361 – 34,359]). These health gains result in an overall gain of 74,499 QALYs (95% UI,
298 21,108 – 160,246), with 63% attributed to males and 37% to females. This translates into CAD\$
299 1,149 million (95% UI, CAD\$ 329 – CAD\$ 2,381) in healthcare cost savings (71% in males,
300 29% in females) over the lifetime of the 2019 Canadian cohort (**Tables 3 and 4, Figure 1 and**
301 **2**).

302 Greater health and healthcare cost gains were projected based on the criteria used by WHO to
303 estimate FOPL cost-effectiveness and results from a FOPL systematic review and network meta-

304 analysis. An increase of 34% and 64% in all outcomes was estimated, respectively, versus the
305 results based on evaluations of the Chilean FOPL (**Tables 3 and 4, Figure 1 and 2**).

306 Sodium intake reduction through consumer food substitution – specifically, when consumers
307 choose food products with fewer ‘high in’ FOPL symbols – has the potential to prevent between
308 35,930 (95% UI, 8,085 – 80,528) and 124,744 (95% UI, 40,125 – 235,643) cases of IHD, and
309 between 26,869 (95% UI, 5,235 – 61,621) and 93,129 (95% UI, 30,296 – 176,014) strokes. This
310 results in QALY gains ranging from 45,492 (95% UI, 10,281 – 106,579) to 157,628 (95% UI,
311 46,701 – 320,622), and healthcare cost savings ranging from CAD\$ 695 million (95% UI, CAD\$
312 160 – CAD\$ 1,580) to CAD\$ 2,415 million (95% UI, CAD\$ 722 – CAD\$ 4,746) over the
313 lifetime of the 2019 Canadian cohort (**Tables 3 and 4, Figure 1 and 2**).

314 All sodium reduction strategies tested in this study were cost saving from the public healthcare
315 system perspective. Estimated benefits were greater for males than females in all scenarios
316 tested.

317 *Sensitivity analysis*

318 We examined the impact of uncertainty in the discount rate by applying discount rates of 3% and
319 0%. When a 3% discount rate was applied to both health and healthcare cost outcomes, a
320 decrease of 44% and 39% were observed on average for QALYs and healthcare costs,
321 respectively, in all scenarios. Conversely, when a 0% discount rate was applied, an increase of
322 96% and 78% were observed on average for QALYs and healthcare costs, respectively, in all
323 scenarios (See **Supplementary Table S10**).

324 Furthermore, using time horizons of 10 and 50 years, the model predicted that 7% and 76%,
325 respectively, of estimated lifetime healthcare cost savings would occur within those time
326 horizons. For QALYs gained, the model estimated that 4% and 67%, respectively, of estimated
327 lifetime gains would occur within those same time horizons (See **Supplementary Table S11**).

328 **4. Discussion**

329 This study estimated the potential impact of reducing sodium intake on the incidence of ischemic
330 heart disease and stroke cases, savings in healthcare costs, and QALYs gains. Our results
331 demonstrate that reducing sodium intakes through population-level strategies, such as
332 implementing sodium reduction targets and ‘high in’ FOPL regulations, has the potential to
333 improve health outcomes and reduce healthcare expenditures in Canada. This adds to current
334 evidence, generated by simulation modeling studies, showing that sodium reduction strategies
335 can potentially improve health outcomes and save costs to the health system, globally(29, 56-62)
336 and in Canada(10, 19).

337 To the best of our knowledge, this is the first study estimating the potential health (QALYs) and
338 healthcare costs of current sodium reduction initiatives in Canada. We tested ten counterfactual
339 scenarios aiming to reduce population sodium intake. These included achieving recommended
340 sodium intakes levels (2,000 and 1,500 mg/day); meeting sodium reduction targets for packaged
341 foods established by Health Canada (food reformulation, 2,300 mg/day); and estimated changes
342 in sodium intake resulting from implementing the recently approved ‘high in’ FOPL regulations.
343 As expected, our results showed the greatest health gains and healthcare cost savings from
344 meeting population-level sodium intake recommendations of 2,000 mg/day (441,475 QALYs;
345 CAD\$ 6,692 million in healthcare costs savings) and 1,500 mg/day (701,592 QALYs; CAD\$

346 10,624 million in healthcare costs savings). Our study sheds light on how far Canadians are from
347 achieving these maximum benefits with current sodium reduction policy initiatives.

348 For instance, for the policy initiatives tested in this study (i.e., meeting sodium reduction targets
349 and implementing ‘high in’ FOPL regulations), most health and healthcare costs gains were
350 attributed to fully meeting Health Canada’s sodium reduction targets (276,185 QALYs; CAD\$
351 4,212 million in healthcare costs savings). Greater benefits were observed for males than
352 females, in all scenarios tested, which could be attributed to differences in sodium consumption
353 and CVD burden among Canadians males and females(9, 10, 63). Unfortunately, progress
354 evaluations have shown that compliance with the voluntary sodium reduction targets has been
355 limited, with only 14% of food categories meeting the targets by 2017(14), indicating that to
356 meet targets by 2025(13) faster progress is needed. A robust government-led monitoring system
357 and higher compliance from the food industry could contribute towards increasing sodium
358 reduction progress in Canada. The consequences of not meeting established sodium reduction
359 targets for processed foods represents an important missed opportunity to generate substantial
360 health and healthcare costs gains in Canada.

361 Canada could benefit from other countries experiences that have implemented mandatory sodium
362 reduction targets. For instance, South Africa’s legislation setting mandatory maximum sodium
363 levels in foods has led to a decrease of 1.15 g/day in salt intake (~460 mg/day of sodium) in a
364 four-year period (2015-2019). Interestingly, similar sodium reduction levels were estimated for
365 our scenario of fully meeting sodium reduction targets(64), which indicates the feasibility of this
366 strategy. This also highlights the importance of changing the voluntary nature of sodium
367 reduction targets in Canada to mandatory sodium reduction targets. More recently, the WHO
368 released the *WHO global sodium benchmarks for different food categories*(65). This set of

369 sodium reduction targets includes 18 main food categories and 97 food subcategories. Greater
370 benefits would be expected from meeting these targets in Canada, given that for several common
371 food categories WHO targets are more stringent than Health Canada's sodium reduction targets.
372 In Australia, it has been estimated that meeting WHO benchmarks, as opposed to meeting
373 Australian sodium reduction targets, could prevent or delay nearly three and a half times as many
374 diet related NCD deaths(62).

375 The potential impact of FOPL regulations was estimated through two pathways. The first was
376 based on recent FOPL evidence from observational and experimental studies(38-40) that
377 estimated changes in the content of nutrients of public health concern, including sodium, in food
378 and beverage purchases when a 'high in' FOPL was in place. Among these scenarios is one
379 based on early evaluations of the Chilean FOPL (S4), which most likely captured consumer
380 behavior change and initial industry-driven food reformulation. The health and healthcare cost
381 gains estimated from this scenario represent approximately 27% of the gains estimated from
382 meeting Health Canada's sodium reduction targets. The second pathway was based on consumer
383 research reporting the proportion of consumers that choose or were willing to choose products
384 with fewer 'high in' FOPL symbols(42-47), which would only capture consumer behavior
385 change. The estimated benefits from these scenarios range from 16% to 57% of the benefits
386 estimated from meeting Health Canada's sodium reduction targets.

387 The differences in FOPL scenarios tested are reflected in our estimates. We observed greater
388 benefits from changes observed in food and beverage purchases in the presence of FOPL (S4-6)
389 than from food substitution as a response of FOPL (S7-9). It is worth noting that our study
390 focused solely on benefits from reducing sodium intake as a result of implementing FOPL in
391 Canada. Therefore, it is expected that implementation of FOPL will result in greater health and

392 healthcare cost benefits, as it also targets other nutrients-of-concern (i.e., sugars and saturated
393 fats) not accounted for in our estimates. For instance, a recent study from our research group
394 estimated that 15% of diet related NCD deaths that could be averted or delayed due to
395 implementation of FOPL in Canada were attributed to sodium(21).

396 A previous Canadian modeling study estimated potential health and healthcare cost benefits, over
397 a 50-year time horizon, from reducing sodium intake levels by 1,500 mg/day(19). They
398 estimated benefits of 1,021,458 QALYs and CAD\$16,805 million in healthcare cost savings(19).
399 In comparison, the largest reduction we tested was a reduction in sodium intake of 1,258 mg/day
400 to achieve the AI recommendations (1,500 mg/day). Under this scenario we projected benefits of
401 471,748 QALYs and CAD\$ 8,083 million in healthcare cost savings over a 50-year time horizon.
402 Differences likely stem from variations in the magnitude of the tested sodium reduction intake
403 (reductions of 1500 mg/day vs. 1,258 mg/day), differences in methodology used to estimate
404 healthcare costs, improved management of SBP in Canada, and slight reductions observed in the
405 burden of CVDs in Canada. In the US a sodium reduction of 1,200 mg/day has been predicted to
406 gain between 194,000 and 392,000 QALYs and save between \$10,000 to \$24,000 million in
407 healthcare costs(66).

408 This study has limitations and strengths that need to be considered in the interpretation of our
409 results. First, scenario modeling is an analytical technique; hence, results are as appropriate and
410 generalizable as the data, assumptions and constraints that are applied to the mathematical
411 model(67). To mitigate this, we used Canadian-specific and nationally representative data as
412 inputs for the model. Additionally, our counterfactual sodium reduction intervention scenarios
413 are based on Canadian sodium reduction targets and the most recent available evidence on the
414 impact of FOPL regulations. We followed the perspective of the public healthcare system; hence,

415 the costs of implementing the sodium reduction interventions were not considered. Although
416 population-wide sodium reduction interventions in Canada were estimated to cost CAD\$2.02 per
417 person annually (Canadian population in 2019: 38 million approximately), these costs would be
418 minimal in comparison with savings in healthcare costs(19, 68). These costs included
419 government led industry agreements to reduce sodium in packaged foods, government
420 monitoring of industry compliance, and public health campaigns(19, 68). We also did not
421 consider societal gains in our modeling, such as productivity gains from preventing premature
422 deaths or disease burden.

423 Furthermore, we focused on the potential health effects of reducing sodium intake, specifically
424 health effects from IHD and stroke, the leading causes of death globally. However, recent studies
425 have estimated potential effects of reducing sodium on other diseases such as chronic kidney
426 disease and stomach cancer(58, 59, 69, 70). Therefore, our estimations of the potential benefits
427 of reducing population-level sodium intake are conservative, considering that reducing sodium
428 intake could also have positive effects on other diseases. Lastly, this study used data for the
429 entire Canadian population without considering equity aspects. Future research can expand our
430 work by examining the differential impacts of reducing sodium intake among diverse subgroups.

431 This study also has strengths to consider. Dietary sodium intake data was estimated using data
432 from a nationally representative sample of the Canadian population (CCHS-Nutrition 2015).
433 Surveys of this kind are usually prone to biases related to misreporting due to recall bias.
434 Nevertheless, CCHS-Nutrition 2015 used the Automated Multiple Pass Method to reduce the
435 impact of such reporting errors. We used the NCI method to estimate usual sodium intakes and
436 adjusted for age, sex, dietary misreporting status, weekend/weekday, and sequence of dietary
437 recall. For modeling we used the PRIMETIME model, a robust, validated and widely used

438 proportional multi-state lifetable model(23, 24). Strengths and limitations of the model have been
439 previously published(24). We also conducted sensitivity analysis to examine the impact of
440 uncertainty in the discount rate by applying 0% and 3% discount rates, as has been
441 recommended(22). As expected, variations in discount rates, both higher and lower than our
442 main analysis (1.5% discount rate), had a significant impact on health and healthcare cost
443 outcomes.

444 Our findings provide evidence for policymakers and stakeholders of the potential benefits of
445 reducing sodium intake through strategies widely discussed in Canada that target packaged
446 foods. This is especially relevant because packaged foods are the main source of sodium intake
447 for Canadians(9). Multicomponent strategies have proven to be more effective and are necessary
448 for reaching the national and global sodium recommendations(11, 71). Therefore, in addition to
449 moving from voluntary to mandatory sodium reduction targets for packaged foods and
450 implementing ‘high in’ FOPL regulations, other initiatives should be considered for Canadians to
451 meet population-level sodium intake recommendations (2,000 and 1,500 mg/day). These could
452 include setting sodium reduction targets for restaurant foods, restricting marketing of foods ‘high
453 in’ sodium, enabling healthy food environments in public settings by providing lower sodium
454 options, regulating the digital food environment to require nutritional information, encouraging
455 the use of low-sodium, potassium-enriched salt, and adopting approaches such as social
456 marketing to develop behavior change communication and mass media campaigns(11, 72, 73). A
457 combination of strategies, as has been recommended by the WHO’s *SHAKE Technical Package
458 for Salt Reduction*(11), would be of most benefit from a public health standpoint.

459 **5. Conclusions**

460 Reducing population-level sodium intakes is feasible and has the potential to improve health
461 outcomes and save healthcare costs in Canada. From the interventions tested most health and
462 healthcare costs gains were attributed to fully meeting sodium reduction targets, which highlights
463 the importance of changing the voluntary nature of these targets to mandatory. A combination of
464 strategies, mandatory sodium reduction targets and implementation of the ‘high in’ FOPL
465 symbol would be of most benefit from a public health standpoint. Thus, policymakers and
466 stakeholders need to strengthen, and coordinate actions aimed at reducing sodium levels in the
467 Canadian food supply. This is crucial for improving health outcomes and saving healthcare costs.
468 Future studies could leverage this work to evaluate potential variations in effects among diverse
469 subgroups in Canada.

470 **Conflict of interest**

471 The authors declare that the research was conducted in the absence of any commercial or
472 financial relationships that could be construed as a potential conflict of interest.

473 **Authors' contributions**

474 NF, AJ, and MRL conceptualized the study design; NF, AJ, BAC, LC, EN and MRL interpreted
475 the findings; NF conducted the study, wrote the original draft, and performed the statistical
476 analysis. All authors critically reviewed and approved the final manuscript.

477 **Funding**

478 This research was funded by Canadian Institutes of Health Research (CIHR) operating grants
479 (PJT-165858; SA2-152805; Healthy Cities Training Award). <https://cihr-irsc.gc.ca/e/193.html>.
480 The funders had no role in study design, data collection and analysis, decision to publish, or
481 preparation of the manuscript.

482 **Acknowledgments**

483 The authors would like to thank Professor Peter Scarborough, University of Oxford, for allowing
484 us to use the PRIMETIME model and discussing its application; as well as current and past
485 L'Abbe lab members who worked on various aspects of the FLIP database, especially Anthea
486 Christoforou who worked and published data on the sodium reformulation scenario used in this
487 manuscript. Furthermore, the authors would like to acknowledge the assistance of Arantxa
488 Bonifaz Rosas with the collection of Canadian healthcare cost data.

489

490 **Data Availability Statement**

491 Analytic code (R) can be made available to researchers upon request to the author. *Canadian*
492 *Community Health Survey-Nutrition 2015 Public Use Microdata File (PUMF)* data is publicly
493 and freely available without restriction at Statistics Canada,
494 <https://www150.statcan.gc.ca/n1/en/catalogue/82M0024X>

495 Canadian population demographics, healthcare costs and epidemiology data associated with
496 ischemic heart disease and stroke were obtained from publicly available sources – also detailed
497 in the main manuscript.

498 <https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=1710000501>

499 <https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=1310070901>

500 <https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=1310014701>

501 <https://health-infobase.canada.ca/ccdss/data-tool/>

502 <https://cost-illness.canada.ca/custom-personnalise/national.php>

503 **Table 1.** Key data sources used for the application of the PRIMETIME Salt model in Canada
 504

Parameter	Data source	Details	Year
Canadian population demographics	Statistics Canada: Table 17-10-0005-01 (Formerly CANSIM 051-0001)	1y age/sex groups 0–100+ years	2019
Deaths	Statistics Canada: Table: 13-10-0709-01 (Formerly CANSIM 102-0503)	5y age/sex groups 0–100+ years	2019
Disease-specific deaths	Statistics Canada: Table: 13-10-0147-01 (Formerly CANSIM 102-0529)	5y age/sex groups 0–90+ years	2019
Disease-specific prevalence	Canadian Chronic Disease Surveillance System	5y age/sex groups 20–90+ years	2019
Disease-specific incidence	Canadian Chronic Disease Surveillance System	5y age/sex groups 20–90+ years	2019
Case fatalities	Were derived from Statistics Canada estimates of incidence, prevalence, and deaths, using the <i>disbayes</i> R package.	1y age/sex groups 0–100+ years	2019
SBP estimates	Statistics Canada: Table: 13-10-0326-01 (Formerly CANSIM 117-0008)	different age/sex groups 6-79 years	2019
Sodium intake	Canadian Community Health Survey-Nutrition 2015	DRI age/sex groups 19+ years	2015
Direct healthcare costs, disease-specific	Economic Burden of Illness in Canada	different age/sex groups 0–75+ years	2010
Consumer price index	Statistics Canada: Table 18-10-0005-01 (Formerly CANSIM 326-0021)	health care sub-index	2019
Utility weights	Parameters used to estimate disease-specific and background utility weights were extracted from a UK catalogue of EQ-5D scores	disease-specific prevalence and incidence weights; and by 10y age bands	2011
Relative risks	Disease associated relative risks were derived from a systematic review and meta-analysis (Per 20 mmHg of SBP)	evidence from prospective studies; different age/sex groups <49-79+ years	2002

505 SBP, systolic blood pressure.


506 **Table 2.** Sodium reduction counterfactual scenarios

507

Counterfactual scenarios	Based on	Parameters modeled	Δ Sodium*	Δ Salt*	
Meeting sodium intake recommendations	S1: AI sodium intake recommendations (1,500 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Estimated sodium intakes by DRI age/sex group	- 1,258 mg/day	- 3.14 g/day
	S2: WHO sodium intake recommendations (2,000 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Estimated sodium intakes by DRI age/sex group	- 758 mg/day	- 1.89 g/day
	S3: Sodium reduction targets for packaged foods, reformulation (2,300 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Food & beverages with a sodium target	- 459 mg/day	- 1.15 g/day
Implementing ‘high in’ FOPL regulations (food and beverage purchases)	S4: Changes in food & beverage purchases (Chilean FOPL experience) (20)	Taillie L, et al (2021) (38)	Changes in sodium content of food & beverage purchases	- 128 mg/day	- 0.32 g/day
	S5: Based on WHO criteria to estimate cost-effectiveness of FOPL policies (20)	WHO (2022) (40)	Changes in sodium content of food & beverage purchases	- 174 mg/day	- 0.44 g/day
	S6: Based on a FOPL systematic review and network meta-analysis (20)	Song J, et al (2021) (39)	Changes in sodium content of food & beverage purchases	- 212 mg/day	- 0.53 g/day
Implementing ‘high in’ FOPL regulations (food substitution)	S7: Based on food substitution for 30% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 73 mg/day	- 0.18 g/day
	S8: Based on food substitution for 50% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 131 mg/day	- 0.33 g/day
	S9: Based on food substitution for 70% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 182 mg/day	- 0.45 g/day
	S10: Based on food substitution for all CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 259 mg/day	- 0.65 g/day


508 *These values are overall intervention effect. Intervention effect by DRI age/sex group, as imputed in the PRIMETIME model, are detailed in Supplementary Table
509 S3. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). We considered the potential impacts of FOPL implementation solely
510 for changes in sodium intakes. FOPL, front-of-pack labeling; WHO, World Health Organization; AI, Adequate Intake; mg, milligram; CCHS, Canadian
511 Community Health Survey.

512 **Figure 1.** Estimated QALY gained over the lifetime of the 2019 cohort, by sex and sodium reduction strategy



513
 514 The potential QALYs gained were estimated using the PRIMETIME model(24), with inputs described in Table 1. Full details of each counterfactual scenario have
 515 been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on WHO sodium intake recommendations of 2,000 mg/day and the AI
 516 recommendations of 1,500 mg/day. The sodium target scenario was based on fully meeting Health Canada’s voluntary sodium reduction targets for packaged
 517 foods. The FOPL–changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL–
 518 food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer
 519 ‘high in’ FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack
 520 labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.

521 **Figure 2.** Estimated healthcare cost savings (CAD\$ million) over the lifetime of the 2019 cohort, by sex and sodium reduction
 522 strategy
 523



524 The potential healthcare cost savings were estimated using the PRIMETIME model(24), with inputs described in Table 1. Full details of each counterfactual
 525 scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on the AI recommendations of 1,500 mg/day and the WHO
 526 sodium intake recommendations of 2,000 mg/day. The sodium target scenario was based on fully meeting Health Canada’s voluntary sodium reduction targets
 527 for packaged foods. The FOPL–changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40).
 528 The FOPL–food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products
 529 with fewer ‘high in’ FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-
 530 pack labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.
 531

532 **Table 3.** Prevented disease incident cases over the lifetime of the cohort, by sex and sodium
533 reduction strategy

Counterfactual scenarios		IHD incidence cases	%	Stroke incidence cases	%
Meeting sodium intake recommendations	S1: Meeting AI sodium intake recommendations (1,500 mg/day)	558,395 (191,157 – 1,032,085)	100%	418,281 (147,760 – 762,689)	100%
	Males (95% UI)	344,273 (111,585 – 647,015)	62%	236,728 (79,646 – 439,265)	57%
	Females (95% UI)	214,123 (79,572 – 385,070)	38%	181,553 (68,114 – 323,425)	43%
	S2: Meeting WHO sodium intake recommendations (2,000 mg/day)	350,142 (117,927 – 649,693)	100%	261,877 (88,387 – 481,374)	100%
	Males (95% UI)	217,586 (70,367 – 410,138)	62%	149,596 (48,512 – 278,702)	57%
	Females (95% UI)	132,556 (47,561 – 239,555)	38%	112,280 (39,875 – 202,672)	43%
	S3: Meeting sodium reduction targets for packaged foods (2,300 mg/day)	219,490 (73,409 – 408,630)	100%	164,435 (56,121 – 305,770)	100%
	Males (95% UI)	137,188 (44,185 – 259,658)	63%	94,522 (31,032 – 179,060)	57%
	Females (95% UI)	82,303 (29,224 – 148,972)	37%	69,913 (25,088 – 126,710)	43%
FOPL – changes in food and beverage purchases	S4: Changes in food & beverage purchases (Chilean experience)	57,023 (17,350 – 114,447)	100%	41,794 (12,389 – 85,302)	100%
	Males (95% UI)	36,323 (10,526 – 73,593)	64%	24,443 (7,028 – 50,943)	58%
	Females (95% UI)	20,701 (6,824 – 40,854)	36%	17,351 (5,361 – 34,359)	42%
	S5: Based on WHO criteria to estimate cost-effectiveness of FOPL policies	76,555 (24,471 – 150,693)	100%	56,322 (18,202 – 111,634)	100%
	Males (95% UI)	48,704 (14,968 – 96,967)	64%	32,914 (10,308 – 65,871)	58%
	Females (95% UI)	27,851 (9,503 – 53,726)	36%	23,409 (7,894 – 45,763)	42%
FOPL – food substitution	S7: Based on food substitution for 30% of CCHS-Nutrition 2015 adult participants	35,930 (8,058 – 80,528)	100%	26,869 (5,235 – 61,621)	100%
	Males (95% UI)	22,968 (5,336 – 51,212)	64%	15,860 (3,221 – 36,350)	59%
	Females (95% UI)	12,962 (2,722 – 29,315)	36%	11,009 (2,013 – 25,271)	41%
	S8: Based on food substitution for 50% of CCHS-Nutrition 2015 adult participants	63,013 (19,800 – 127,007)	100%	46,868 (14,668 – 94,881)	100%
	Males (95% UI)	40,472 (12,467 – 82,378)	64%	27,767 (8,508 – 56,851)	59%
	Females (95% UI)	22,541 (7,332 – 44,628)	36%	19,101 (6,160 – 38,030)	41%
	S9: Based on food substitution for 70% of CCHS-Nutrition 2015 adult participants	86,135 (28,713 – 166,394)	100%	63,961 (21,187 – 124,102)	100%
	Males (95% UI)	55,461 (17,911 – 108,730)	64%	37,984 (12,216 – 74,661)	59%
Females (95% UI)	30,674 (10,802 – 57,664)	36%	25,977 (8,971 – 49,441)	41%	
FOPL – food substitution	S10: Based on food substitution for all CCHS-Nutrition 2015 adult participants	124,744 (40,125 – 235,643)	100%	93,129 (30,296 – 176,014)	100%
	Males (95% UI)	78,998 (24,224 – 151,268)	63%	54,299 (16,845 – 104,141)	58%
	Females (95% UI)	45,746 (15,901 – 84,375)	37%	38,830 (13,451 – 71,873)	42%

534

535 The potential health impacts were estimated using the PRIMETIME model(24), with inputs described in Table 1. Full
536 details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios
537 were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake recommendations of
538 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health Canada’s voluntary sodium
539 reduction targets for packaged foods. The FOPL–changes in F&B purchase scenarios (S4-6) were based on recent
540 FOPL evidence from observational and experimental studies(38-40). The FOPL–food substitution scenarios (S7-10)
541 were based on consumer research reporting the proportion of consumers that choose or were willing to choose
542 products with fewer ‘high in’ FOPL symbols(42-47). We considered the potential impacts of FOPL implementation
543 solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, ischemic heart disease; WHO, World
544 Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey.

545 **Table 4.** Estimated health gains and healthcare cost savings over the lifetime of the cohort, by
 546 sex and sodium reduction strategy

Counterfactual scenarios		QALY gains	%	Healthcare cost savings (CAD\$ million)	%
Meeting sodium intake recommendations	S1: Meeting AI sodium intake recommendations (1,500 mg/day)	701,592 (225,679 – 1,393,230)	100%	10,624 (3,356 – 20,665)	100%
	Males (95% UI)	425,297 (126,968 – 860,372)	61%	7,295 (2,183 – 14,410)	69%
	Females (95% UI)	276,295 (98,711 – 532,858)	39%	3,329 (1,173 – 6,255)	31%
	S2: Meeting WHO sodium intake recommendations (2,000 mg/day)	441,475 (135,508 – 891,597)	100%	6,692 (2,092 – 13,017)	100%
	Males (95% UI)	269,816 (77,889 – 555,809)	61%	4,626 (1,383 – 9,108)	69%
	Females (95% UI)	171,659 (57,619 – 335,788)	39%	2,067 (708 – 3,909)	31%
	S3: Meeting sodium reduction targets for packaged foods (2,300 mg/day)	276,185 (85,414 – 552,616)	100%	4,212 (1,303 – 8,206)	100%
	Males (95% UI)	169,889 (50,166 – 344,868)	62%	2,926 (868 – 5,769)	69%
	Females (95% UI)	106,296 (35,248 – 207,748)	38%	1,286 (435 – 2,437)	31%
FOPL – changes in food and beverage purchases	S4: Changes in food & beverage purchases (Chilean experience)	74,499 (21,108 – 160,246)	100%	1,149 (329 – 2,381)	100%
	Males (95% UI)	46,889 (12,607 – 102,243)	63%	814 (220 – 1,708)	71%
	Females (95% UI)	27,609 (8,501 – 58,003)	37%	336 (109 – 673)	29%
	S5: Based on WHO criteria to estimate cost-effectiveness of FOPL policies	99,867 (29,314 – 210,195)	100%	1,535 (455 – 3,119)	100%
	Males (95% UI)	62,782 (17,670 – 134,336)	63%	1,085 (308 – 2,231)	71%
	Females (95% UI)	37,084 (11,644 – 75,859)	37%	449 (147 – 888)	29%
FOPL – food substitution	S7: Based on food substitution for 30% of CCHS-Nutrition 2015 adult participants	45,492 (10,281 – 106,579)	100%	695 (160 – 1,580)	100%
	Males (95% UI)	28,620 (6,375 – 68,250)	63%	492 (110 – 1,123)	71%
	Females (95% UI)	16,872 (3,906 – 38,329)	37%	204 (50 – 457)	29%
	S8: Based on food substitution for 50% of CCHS-Nutrition 2015 adult participants	80,321 (23,373 – 169,543)	100%	1,231 (367 – 2,549)	100%
Males (95% UI)	50,867 (14,373 – 108,277)	63%	875 (254 – 1,835)	71%	
Females (95% UI)	29,454 (9,001 – 61,265)	37%	356 (113 – 714)	29%	
FOPL – food substitution	S9: Based on food substitution for 70% of CCHS-Nutrition 2015 adult participants	110,063 (34,011 – 228,868)	100%	1,688 (512 – 3,427)	100%
	Males (95% UI)	69,860 (20,880 – 147,630)	63%	1,202 (351 – 2,468)	71%
	Females (95% UI)	40,203 (13,131 – 81,239)	37%	486 (161 – 959)	29%
	S10: Based on food substitution for all CCHS-Nutrition 2015 adult participants	157,628 (46,701 – 320,622)	100%	2,415 (722 – 4,746)	100%
Males (95% UI)	98,309 (27,375 – 203,349)	62%	1,696 (482 – 3,376)	70%	
Females (95% UI)	59,318 (19,326 – 117,273)	38%	719 (239 – 1,370)	30%	

547 The potential health gains and healthcare cost savings were estimated using the PRIMETIME model(24), with inputs
548 described in Table 1. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium
549 intake goal scenarios were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake
550 recommendations of 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health
551 Canada’s voluntary sodium reduction targets for packaged foods. The FOPL–changes in F&B purchase scenarios
552 (S4-6) were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL–food
553 substitution scenarios (S7-10) were based on consumer research reporting the proportion of consumers that choose
554 or were willing to choose products with fewer ‘high in’ FOPL symbols(42-47). We considered the potential impacts
555 of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, WHO, World
556 Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey;
557 QALY, Quality-Adjusted Life Year; CAD\$, Canadian dollars.

558 **References**

- 559 1. Institute for Health Metrics and Evaluation (IHME). GBD Compare Seattle, WA: IHME,
560 University of Washington, 2019.2019 [Available from: [http://vizhub.healthdata.org/gbd-](http://vizhub.healthdata.org/gbd-compare)
561 [compare](http://vizhub.healthdata.org/gbd-compare).
- 562 2. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global
563 sodium consumption and death from cardiovascular causes. *New England Journal of Medicine*.
564 2014;371(7):624-34.
- 565 3. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C,
566 et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for
567 the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A
568 Report of the American College of Cardiology/American Heart Association Task Force on
569 Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2018;71(19):e127-
570 e248.
- 571 4. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al.
572 Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD
573 2019 study. *Journal of the American College of Cardiology*. 2020;76(25):2982-3021.
- 574 5. World Health Organization. Noncommunicable diseases country profiles 2018 2018
575 [Available from: <https://apps.who.int/iris/handle/10665/274512>.
- 576 6. World Health Organization. Tackling NCDs: 'best buys' and other recommended
577 interventions for the prevention and control of noncommunicable diseases 2017 [Available from:
578 <https://apps.who.int/iris/handle/10665/259232>.
- 579 7. World Health Organization. Saving lives, spending less: a strategic response to
580 noncommunicable diseases Geneva, Switzerland.2018 [Available from:
581 <https://apps.who.int/iris/handle/10665/272534>.
- 582 8. World Health Organization. Salt reduction 2020 [Available from:
583 <https://www.who.int/news-room/fact-sheets/detail/salt-reduction>.
- 584 9. Health Canada. Sodium Intake of Canadians in 2017 2018 [Available from:
585 [https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-](https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf)
586 [nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf](https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf).
- 587 10. Flexner N, Christoforou AK, Bernstein JT, Ng AP, Yang Y, Fernandes Nilson EA, et al.
588 Estimating Canadian sodium intakes and the health impact of meeting national and WHO
589 recommended sodium intake levels: A macrosimulation modelling study. *PLOS ONE*.
590 2023;18(5):e0284733.
- 591 11. World Health Organization. The SHAKE Technical Package for Salt Reduction. Geneva:
592 WHO;2016. [Available from:
593 <https://apps.who.int/iris/bitstream/handle/10665/250135/9789241511346-eng.pdf?sequence=1>.
- 594 12. Health Canada. Healthy Eating Strategy 2016 [Available from:
595 [https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-](https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-strategy.html)
596 [strategy.html](https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-strategy.html).
- 597 13. Government of Canada. Voluntary sodium reduction targets for processed foods 2020-
598 2025 2020 [Available from: [https://www.canada.ca/en/health-canada/services/food-](https://www.canada.ca/en/health-canada/services/food-nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html)
599 [nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html](https://www.canada.ca/en/health-canada/services/food-nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html).
- 600 14. Health Canada. Sodium Reduction in Processed Foods in Canada: An Evaluation of
601 Progress toward Voluntary Targets from 2012 to 2016 2018 [Available from:
602 [34](https://www.canada.ca/content/dam/hc-sc/documents/services/food-nutrition/legislation-</div><div data-bbox=)

- 603 [guidelines/guidance-documents/guidance-food-industry-reducing-sodium-processed-foods-](#)
604 [progress-report-2017/pub1-eng.pdf](#).
- 605 15. Government of Canada. Regulations Amending the Food and Drug Regulations (Nutrition
606 Symbols, Other Labelling Provisions, Vitamin D and Hydrogenated Fats or Oils): SOR/2022-
607 168 2022 [Available from: [https://canadagazette.gc.ca/rp-pr/p2/2022/2022-07-20/html/sor-
609 dors168-eng.html](https://canadagazette.gc.ca/rp-pr/p2/2022/2022-07-20/html/sor-
608 dors168-eng.html)].
- 609 16. Scarborough P, Harrington RA, Mizdrak A, Zhou LM, Doherty A. The preventable risk
610 integrated ModEl and its use to estimate the health impact of public health policy scenarios.
611 *Scientifica*. 2014;2014.
- 612 17. Webber L, Mytton OT, Briggs AD, Woodcock J, Scarborough P, McPherson K, et al.
613 The Brighton declaration: the value of non-communicable disease modelling in population health
614 sciences. *European journal of epidemiology*. 2014;29:867-70.
- 615 18. Hope SF, Webster J, Trieu K, Pillay A, Ieremia M, Bell C, et al. A systematic review of
616 economic evaluations of population-based sodium reduction interventions. *PLoS One*.
617 2017;12(3):e0173600.
- 618 19. Qureshi H. The Economic Impact of Dietary Sodium Reduction in Canada. Calgary,
619 Canada: University of Calgary; 2017.
- 620 20. Flexner N, Ng AP, Ahmed M, Khandpur N, Acton RB, Lee JJ, et al. Estimating the
621 dietary and health impact of implementing front-of-pack nutrition labeling in Canada: A
622 macrosimulation modeling study. *Frontiers in Nutrition*. 2023;10.
- 623 21. Flexner N, Ahmed M, Mulligan C, Bernstein JT, Christoforou AK, Lee JJ, et al. The
624 estimated dietary and health impact of implementing the recently approved 'high in' front-of-
625 package nutrition symbol in Canada: a food substitution scenario modeling study. *Frontiers in*
626 *Nutrition*. 2023;10.
- 627 22. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the
628 economic evaluation of health technologies: Canada. Ottawa: CADTH; 2017 Mar.
- 629 23. Dötsch-Klerk M, Bruins MJ, Detzel P, Martikainen J, Nergiz-Unal R, Roodenburg AJ, et al.
630 Modelling health and economic impact of nutrition interventions: a systematic review.
631 *European Journal of Clinical Nutrition*. 2022;1-14.
- 632 24. Cobiac LJ, Law C, Scarborough P. PRIMETIME: an epidemiological model for informing
633 diet and obesity policy. *medRxiv*. 2022:2022.05.18.22275284.
- 634 25. Cobiac LJ, Scarborough P, Kaur A, Rayner M. The Eatwell guide: modelling the health
635 implications of incorporating new sugar and fibre guidelines. *PLoS One*. 2016;11(12).
- 636 26. Briggs ADM, Cobiac LJ, Wolstenholme J, Scarborough P. PRIMETIME CE: a multistate
637 life table model for estimating the cost-effectiveness of interventions affecting diet and physical
638 activity. *BMC Health Serv Res*. 2019;19(1):485.
- 639 27. Kent S, Aveyard P, Astbury N, Mihaylova B, Jebb SA. Is Doctor Referral to a Low-
640 Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?
641 *Obesity*. 2019;27(3):391-8.
- 642 28. Mytton OT, Boyland E, Adams J, Collins B, O'Connell M, Russell SJ, et al. The
643 potential health impact of restricting less-healthy food and beverage advertising on UK television
644 between 05.30 and 21.00 hours: A modelling study. *PLoS medicine*. 2020;17(10):e1003212.
- 645 29. Alonso S, Tan M, Wang C, Kent S, Cobiac L, MacGregor GA, et al. Impact of the 2003
646 to 2018 Population Salt Intake Reduction Program in England: A Modeling Study. *Hypertension*.
647 2021;77(4):1086-94.

- 648 30. Cobiac LJ, Scarborough P. Modelling the health co-benefits of sustainable diets in the
649 UK, France, Finland, Italy and Sweden. *European journal of clinical nutrition*. 2019;73(4):624-
650 33.
- 651 31. Aminde LN, Phung HN, Phung D, Cobiac LJ, Veerman JL. Dietary salt reduction,
652 prevalence of hypertension and avoidable burden of stroke in Vietnam: modelling the health and
653 economic impacts. *Frontiers in public health*. 2021;9:682975.
- 654 32. Jackson C. Bayesian estimation of chronic disease epidemiology from incomplete data:
655 the disbayes package 2023 [Available from:
656 <https://chjackson.github.io/disbayes/articles/disbayes.html#data-required-by-the-bayesian-model>.
657 33. World Health Organization. International Statistical Classification of Diseases and
658 Related Health Problems 10th Revision 2016 [Available from:
659 <https://icd.who.int/browse10/2016/en#/I20-I25>.
660 34. Jackson C, Zapata-Diomedí B, Woodcock J. Bayesian multistate modelling of incomplete
661 chronic disease burden data. *Journal of the Royal Statistical Society Series A: Statistics in*
662 *Society*. 2023;186(1):1-19.
- 663 35. Health Canada. 2015 Canadian Community Health Survey - Nutrition. Reference Guide
664 to Understanding and Using the Data 2017 [Available from: [https://www.canada.ca/en/health-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/reference-guide-understanding-using-data-2015.html)
665 [canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/reference-guide-understanding-using-data-2015.html)
666 [community-health-survey-cchs/reference-guide-understanding-using-data-2015.html](https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/reference-guide-understanding-using-data-2015.html).
667 36. National Academies of Sciences Engineering and Medicine. Dietary Reference Intakes
668 Collection 2022 [Available from: [https://nap.nationalacademies.org/collection/57/dietary-](https://nap.nationalacademies.org/collection/57/dietary-reference-intakes)
669 [reference-intakes](https://nap.nationalacademies.org/collection/57/dietary-reference-intakes).
670 37. Bernstein JT, Christoforou AK, Flexner N, L'Abbe MR. Comparing the nutritional
671 composition of foods and beverages in the Canadian Nutrient File to a large representative
672 database of Canadian prepackaged foods and beverages. *PLOS ONE*. 2023;18(3):e0280028.
- 673 38. Taillie LS, Bercholz M, Popkin B, Reyes M, Colchero MA, Corvalán C. Changes in food
674 purchases after the Chilean policies on food labelling, marketing, and sales in schools: a before
675 and after study. *The Lancet Planetary Health*. 2021;5(8):e526-e33.
- 676 39. Song J, Brown MK, Tan M, MacGregor GA, Webster J, Campbell NR, et al. Impact of
677 color-coded and warning nutrition labelling schemes: A systematic review and network meta-
678 analysis. *PLoS Medicine*. 2021;18(10):e1003765.
- 679 40. World Health Organization. Technical briefing for Appendix 3 of the Global Action Plan
680 for Non-Communicable Diseases 2022 [Available from:
681 [https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-](https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-ncd-action-plan-2013-2030)
682 [ncd-action-plan-2013-2030](https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-ncd-action-plan-2013-2030).
683 41. Appelhans BM, French SA, Tangney CC, Powell LM, Wang Y. To what extent do food
684 purchases reflect shoppers' diet quality and nutrient intake? *International Journal of Behavioral*
685 *Nutrition and Physical Activity*. 2017;14(1):1-10.
- 686 42. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la Ley
687 sobre composición nutricional de los alimentos y su publicidad 2017 [Available from:
688 [https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementaci%C3%B3n-Ley-](https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementaci%C3%B3n-Ley-20606-junio-2017-PDF.pdf)
689 [20606-junio-2017-PDF.pdf](https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementaci%C3%B3n-Ley-20606-junio-2017-PDF.pdf).
690 43. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la ley sobre
691 composición nutricional de los alimentos y su publicidad 2018 [Available from:
692 [https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementación-Ley-20606-](https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementación-Ley-20606-febrero-18-1.pdf)
693 [febrero-18-1.pdf](https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementación-Ley-20606-febrero-18-1.pdf).

- 694 44. Ministerio de Salud de Chile. Informe sobre evaluaciones de la Ley N° 20.606 sobre
695 composicion nutricional de los alimentos y su publicidad 2021 [Available from:
696 [https://www.minsal.cl/wp-content/uploads/2022/02/EVALUACION-LEY-DE-ALIMENTOS-
697 oct2021.pdf](https://www.minsal.cl/wp-content/uploads/2022/02/EVALUACION-LEY-DE-ALIMENTOS-
697 oct2021.pdf).
698 45. Bromberg M, Sinai T, Keinan-Boker L, Endevelt R, Frankenthal D. Current use of
699 nutrition facts tables and attitudes towards new red and green front-of-package labels among
700 Israeli consumers. *International Journal of Food Sciences and Nutrition*. 2022;73(2):230-7.
701 46. Shahrabani S. The impact of Israel’s Front-of-Package labeling reform on consumers’
702 behavior and intentions to change dietary habits. *Israel Journal of Health Policy Research*.
703 2021;10(1):1-11.
704 47. Mansfield ED, Ibanez D, Chen F, Chen E, de Grandpré E. Efficacy of “High in” Nutrient
705 Specific Front of Package Labels—A Retail Experiment with Canadians of Varying Health
706 Literacy Levels. *Nutrients*. 2020;12(10):3199.
707 48. Public Health Agency of Canada. Economic Burden of Illness in Canada, 2010 2018
708 [Available from: [https://www.canada.ca/en/public-health/services/publications/science-research-
709 data/economic-burden-illness-canada-2010.html](https://www.canada.ca/en/public-health/services/publications/science-research-
709 data/economic-burden-illness-canada-2010.html).
710 49. Jones AC. Predicting the potential health and economic impact of a sugary drink tax in
711 Canada: a modelling study: UWSpace; 2018.
712 50. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2019 (GBD
713 2019) Data Resources 2019 [Available from: <https://ghdx.healthdata.org/gbd-2019>.
714 51. Government of Canada. Economic Burden of Illness in Canada custom report generator
715 2010 [Available from: <https://cost-illness.canada.ca/custom-personnalise/national.php>.
716 52. Krueger H, Krueger J, Koot J. Variation across Canada in the economic burden
717 attributable to excess weight, tobacco smoking and physical inactivity. *Canadian journal of
718 Public health*. 2015;106(4):e171-e7.
719 53. Canada S. Consumer Price Index, annual average, not seasonally adjusted. Statistics
720 Canada: Table 18-10-0005-01 (formerly CANSIM 326-0021) 2019 [Available from:
721 <https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000501>.
722 54. National Cancer Institute. Usual Dietary Intakes: SAS Macros for the NCI Method 2018
723 [Available from: <https://epi.grants.cancer.gov/diet/usualintakes/macros.html>.
724 55. Davis KA, Gonzalez A, Loukine L, Qiao C, Sadeghpour A, Vigneault M, et al. Early
725 experience analyzing dietary intake data from the Canadian Community Health Survey—
726 nutrition using the National Cancer Institute (NCI) method. *Nutrients*. 2019;11(8):1908.
727 56. Nilson EAF, Pearson-Stuttard J, Collins B, Guzman-Castillo M, Capewell S, O’Flaherty
728 M, et al. Estimating the health and economic effects of the voluntary sodium reduction targets in
729 Brazil: microsimulation analysis. *BMC medicine*. 2021;19(1):1-10.
730 57. Shangquan S, Mozaffarian D, Sy S, Lee Y, Liu J, Wilde PE, et al. Health Impact and
731 Cost-Effectiveness of Achieving the National Salt and Sugar Reduction Initiative Voluntary
732 Sugar Reduction Targets in the United States: A Micro-Simulation Study. *Circulation*. 2021.
733 58. Aminde LN, Wanjau MN, Cobiac LJ, Veerman JL. Estimated Impact of Achieving the
734 Australian National Sodium Reduction Targets on Blood Pressure, Chronic Kidney Disease
735 Burden and Healthcare Costs: A Modelling Study. *Nutrients*. 2023;15(2).
736 59. Aminde LN, Cobiac LJ, Phung D, Phung HN, Veerman JL. Avoidable burden of stomach
737 cancer and potential gains in healthy life years from gradual reductions in salt consumption in
738 Vietnam, 2019–2030: A modelling study. *Public Health Nutrition*. 2023;26(3):586-97.

- 739 60. Aminde LN, Cobiac L, Veerman JL. Cost-effectiveness analysis of population salt
740 reduction interventions to prevent cardiovascular disease in Cameroon: mathematical modelling
741 study. *BMJ open*. 2020;10(11):e041346.
- 742 61. Trieu K, Coyle DH, Afshin A, Neal B, Marklund M, Wu JH. The estimated health impact
743 of sodium reduction through food reformulation in Australia: A modeling study. *PLoS Medicine*.
744 2021;18(10):e1003806.
- 745 62. Trieu K, Coyle DH, Rosewarne E, Shahid M, Yamamoto R, Nishida C, et al. Estimated
746 Dietary and Health Impact of the World Health Organization's Global Sodium Benchmarks on
747 Packaged Foods in Australia: a Modeling Study. *Hypertension*. 2023.
- 748 63. Pacheco C, Mullen KA, Coutinho T, Jaffer S, Parry M, Van Spall HGC, et al. The
749 Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and
750 Management of Cardiovascular Disease in Women - Chapter 5: Sex- and Gender-Unique
751 Manifestations of Cardiovascular Disease. *CJC Open*. 2022;4(3):243-62.
- 752 64. Charlton KE, Corso B, Ware L, Schutte AE, Wepener L, Minicuci N, et al. Effect of
753 South Africa's interim mandatory salt reduction programme on urinary sodium excretion and
754 blood pressure. *Preventive medicine reports*. 2021;23:101469.
- 755 65. World Health Organization. WHO global sodium benchmarks for different food
756 categories. Geneva: WHO;2021. [Available from:
757 <https://www.who.int/publications/i/item/9789240025097>.
- 758 66. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ,
759 et al. Projected effect of dietary salt reductions on future cardiovascular disease. *New England*
760 *Journal of Medicine*. 2010;362(7):590-9.
- 761 67. Grieger JA, Johnson BJ, Wycherley TP, Golley RK. Evaluation of Simulation Models
762 that Estimate the Effect of Dietary Strategies on Nutritional Intake: A Systematic Review. *The*
763 *Journal of Nutrition*. 2017;147(5):908-31.
- 764 68. Webb M, Fahimi S, Singh GM, Khatibzadeh S, Micha R, Powles J, et al. Cost
765 effectiveness of a government supported policy strategy to decrease sodium intake: global
766 analysis across 183 nations. *Bmj*. 2017;356.
- 767 69. Kim J, Oh A, Truong H, Laszkowska M, Camargo MC, Abrams J, et al. Low sodium diet
768 for gastric cancer prevention in the United States: Results of a Markov model. *Cancer Medicine*.
769 2020.
- 770 70. Kypridemos C, Guzman-Castillo M, Hyseni L, Hickey GL, Bandosz P, Buchan I, et al.
771 Estimated reductions in cardiovascular and gastric cancer disease burden through salt policies in
772 England: an IMPACTNCD microsimulation study. *BMJ open*. 2017;7(1):e013791.
- 773 71. Park H-K, Lee Y, Kang B-W, Kwon K-i, Kim J-W, Kwon O-S, et al. Progress on sodium
774 reduction in South Korea. *BMJ Global Health*. 2020;5(5):e002028.
- 775 72. Arcand J, Campbell NR. Dietary sodium reduction in Canada: more action is needed to
776 reach the 2025 global targets. *CMAJ*. 2022;194(10):E387-E8.
- 777 73. Greer RC, Marklund M, Anderson CA, Cobb LK, Dalcin AT, Henry M, et al. Potassium-
778 enriched salt substitutes as a means to lower blood pressure: benefits and risks. *Hypertension*.
779 2020;75(2):266-74.

780